Has Joaquin Bellmunt Molins, MD received payments from drug or device companies?

Yes. Drug and device makers reported $415,376 in general payments to Joaquin Bellmunt Molins, MD across 229 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joaquin Bellmunt Molins, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joaquin Bellmunt Molins, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joaquin Bellmunt Molins, MD

Medical Oncology · Boston, MANPI 1124462726

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Merck at 38.4% of the total. Among medical oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$415,376in general payments, 2019–2025

Across 229 payments — averaging $1813.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$160K
Astellas Pharma Europe Ltd$52K
Pfizer$36K
Merck Kgaa$36K
Gilead$16K
EMD Serono, Inc.$14K
plus $101K from 20 others

$598,330in research payments, 2019–2025

Across 31 payments — averaging $19,301 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$546K
Gilead$25K
Takeda Pharmaceuticals U.S.A., Inc.$15K
F. Hoffmann-la Roche AG$7K
AstraZeneca$6K

What the payments were for

Consulting fees$201,74849%
Speaking & faculty fees$126,93031%
Travel & lodging$71,97217%
Food & beverage$4,0941%
Education$10,6323%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	90	$159,699
Astellas Pharma Europe Ltd	6	$52,349
Pfizer	27	$36,440
Merck Kgaa	6	$36,015
Gilead	14	$16,092
EMD Serono, Inc.	25	$13,716
Astrazeneca UK Limited	11	$13,266
EMD Serono Research & Development Institute, Inc.	4	$10,673
F. Hoffmann-la Roche AG	5	$10,549
Ipsen Innovation	2	$10,475
AstraZeneca	9	$8,595
Ares Trading SA	3	$8,285
Pfizer Chile S.A.	2	$7,400
E.r. Squibb & Sons, L.L.C.	7	$6,089
Seagen Inc.	4	$4,699
Astellas Pharma US Inc	2	$4,075
Regeneron	1	$3,930
Ipsen Pharma SAS	1	$3,045
Daiichi Sankyo Inc.	2	$2,740
Eisai Inc.	1	$2,040
Chromacode, Inc	1	$2,000
Eli Lilly	2	$1,713
Helsinn Healthcare SA	1	$1,400
Genentech, Inc.	1	$45
Sanofi-aventis U.S. LLC	1	$32
Roche Products Limited	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PADCEV$54,563
BAVENCIO$30,857
Vyloy$10,686
TECENTRIQ$10,549
Trodelvy$9,090
IMFINZI$7,307
TALZENNA$7,050
Enhertu$4,966
KEYTRUDA$4,837
LIBTAYO$3,930
LENVIMA$2,040
OPDIVO$633

How this compares

$415,376 in reported general payments places this provider in the 95th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$47,735

Medicare patients

152

Services billed

398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ondansetron OdtOndansetron	19	$374
Gabapentin	12	$340
Dexamethasone	23	$206

Paid to pharmacies, not to this prescriber.

Other medical oncology in Boston

George DemetriBoston$1.6M
Keith FlahertyBoston$932K
Alicia MorgansBoston$690K
Pasi Antero JanneBoston$458K
Robert HaddadBoston$451K
Irene GhobrialBoston$431K
Jeremy AbramsonBoston$334K
Justin GainorBoston$324K
Narjust FlorezBoston$324K
Reid MerrymanBoston$300K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →